Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression a SPECT study

Journal of Clinical Psychopharmacology

Volumn 36, Issue 1, 2016, Pages 77-81

  Sanches, Rafael Faria ^a,b   De Lima Osório, Flávia ^a,c   Santos, Rafael G Dos ^a   Macedo, Ligia R H ^a   Maia De Oliveira, João Paulo ^a,c,d   Wichert Ana, Lauro ^a   De Araujo, Draulio Barros ^e,f   Riba, Jordi ^b,g,h   Crippa, José Alexandre S ^a,c   Hallak, Jaime E C ^a,c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c National Institute of Science and Technology for Complex Systems   (Brazil)

^d Department of Clinical Medicine ^*  (Brazil)

^e Department of Pediatrics University Hospital Onofre Lopes   (Brazil)

^f FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^g UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^h CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

Ayahuasca; Dimethyltryptamine; Harmine; Monoamine oxidase inhibitors

Indexed keywords

ANTIDEPRESSANT AGENT; AYAHUASCA; UNCLASSIFIED DRUG; PLANT MEDICINAL PRODUCT; PSYCHEDELIC AGENT;

ADULT; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN BLOOD FLOW; BRAIN PERFUSION; BRIEF PSYCHIATRIC RATING SCALE; CINGULATE GYRUS; CLINICAL ARTICLE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; INSULA; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NUCLEUS ACCUMBENS; OPEN STUDY; PRIORITY JOURNAL; RECURRENT DISEASE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; VOMITING; YOUNG MANIA RATING SCALE; BANISTERIOPSIS; BRAIN; CHEMISTRY; CLINICAL TRIAL; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; TIME FACTOR; TREATMENT OUTCOME; VASCULARIZATION;

ADMINISTRATION, ORAL; ADULT; ANTIDEPRESSIVE AGENTS; BANISTERIOPSIS; BRAIN; DEPRESSIVE DISORDER, MAJOR; FEMALE; HALLUCINOGENS; HUMANS; MALE; MIDDLE AGED; PLANT PREPARATIONS; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 84952978708     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000436     Document Type: Article

References (28)

1. McKenna D, Riba J. New World tryptamine hallucinogens and the neuroscience of ayahuasca. Curr Top Behav Neurosci. 2015; in press.
2. Riba J, Valle M, Urbano G, et al. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther. 2003;306:73-83.
3. Riba J, Romero S, Grasa E, et al. Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology (Berl). 2006;186:93-98.
4. dos Santos RG, Osório FL, Crippa JA, et al. Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies. Rev Bras Psiquiatr. 2015; in press.
5. Osório FL, Sanches RF, Macedo LRH, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Rev Bras Psiquiatr. 2015;37:13-20.
6. Labate BC, Cavnar C (Eds). The therapeutic use of ayahuasca. Berlin: Springer; 2014.
7. Del-Ben CM, Vilela JAA, Crippa JAS, et al. Reliability of the structured clinical interview for DSM-IV-clinical version translated into Portuguese. Rev Bras Psiquiatr. 2001;23:156-159.
8. Moreno RA, Moreno DH. Hamilton (HAM-D) & Montgomery & Asberg (MADRS) depression rating scales. Rev Psiquiatr Clín. 1998;25:262-272.
9. Vilela JA, Crippa JA, Del-Ben CM, et al. Reliability and validity of a Portuguese version of the YoungMania Rating Scale. Braz J Med Biol Res. 2005;38:1429-1439.
10. Crippa JA, Sanches RF, Hallak JE, et al. Factor structure of Bech's version of the Brief Psychiatric Rating Scale in Brazilian patients. Braz J Med Biol Res. 2002;35:1209-1213.
11. Hallak JE, Dursun SM, Bosi DC, et al. The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:198-202.
12. Szmulewicz AG, Valerio MP, Smith JM. Switch to mania after ayahuasca consumption in a man with bipolar disorder: a case report. Int J Bipolar Disord. 2015;3:4.
13. Drevets WC, Savitz J, Trimble M. The subgenual anterior cingulate cortex in mood disorders. CNS Spectr. 2008;13:663-681.
14. Pizzagalli DA, Holmes AJ, Dillon DG, et al. Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. Am J Psychiatry. 2009;166:702-710.
15. Fitzgerald PB, Laird AR, Maller J, et al. A meta-analytic study of changes in brain activation in depression. Hum Brain Mapp. 2008;29:683-695.
16. Bewernick BH, Hurlemann R, Matusch A, et al. Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Biol Psychiatry. 2010;67:110-116.
17. Merkl A, Schneider GH, Schönecker T, et al. Antidepressant effects after short-term and chronic stimulation of the subgenual cingulate gyrus in treatment-resistant depression. Exp Neurol. 2013;249:160-168.
18. Masuda Y, Sugiyama T. The effect of globopentaosylceramide on a depression model, mouse forced swimming. Tohoku J Exp Med. 2000;191:47-54.
19. Nic Dhonnchadha BA, Hascoët M, Jolliet P, et al. Evidence for a 5-HT2A receptor mode of action in the anxiolytic-like properties of DOI in mice. Behav Brain Res. 2003;147:175-184.
20. Riba J, McIlhenny EH, Bouso JC, et al. Metabolism and urinary disposition of N, N-dimethyltryptamine after oral and smoked administration: a comparative study. Drug Test Anal. 2015;7:401-406.
21. Kraehenmann R, Preller KH, Scheidegger M, et al. Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry. 2015;78:572-581; in press.
22. Schmid Y, Enzler F, Gasser P, et al. Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry. 2015;78:544-553; in press.
23. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68:71-78.
24. Gasser P, Holstein D, Michel Y, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J NervMentDis. 2014;202:513-520.
25. Palhano-Fontes F, Andrade KC, Tofoli LF, et al. The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PLoS One. 2015;10:e0118143.
26. Carhart-Harris R, Erritzoe D, Williams T, et al. Neural correlates of the psychedelic state as determined by fMRI studieswith psilocybin. Proc Natl Acad Sci USA. 2012;109:2138-2143.
27. Vollenweider FX, Leenders KL, Scharfetter C, et al. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology. 1997;16:357-372.
28. Tupper KW, Labate BC. Ayahuasca, psychedelic studies and health sciences: the politics of knowledge and inquiry into an Amazonian plant brew. Curr Drug Abuse Rev. 2014;7:71-80